FDA OTC Switch Risk Mitigation Strategy for US Sponsors in 2023 – Insight 2 FDA OTC Switch Risk Mitigation Strategy for US Sponsors in 2023 – Insight 2 Step 1: Understanding the Rx to OTC Switch Process The Rx to OTC switch process acknowledges that certain prescription medications can be safely and effectively reclassified as over-the-counter (OTC) drugs. This classification offers significant benefits, including increased consumer access and reduced healthcare costs. For sponsors contemplating this switch in the United States, a thorough understanding of the process and its implications is imperative. The initial step involves assessing the medication in question…

GMP Compliance for Combination Products: Drug and Device Integration GMP Compliance for Combination Products: Drug and Device Integration In the complex landscape of modern pharmaceuticals and medical devices, the integration of drug and device components into combination products has become increasingly prominent. The regulatory framework governing these hybrid products, particularly within the United States, mandates stringent compliance with Good Manufacturing Practices (GMP) as outlined in 21 CFR Part 4. This article serves as a comprehensive guide for regulatory affairs professionals, regulatory operations teams, quality assurance entities, and commercial stakeholders involved in the development and approval of combination products. The following…

Key Differences in Combination Product Regulation: FDA vs EMA Key Differences in Combination Product Regulation: FDA vs EMA Combination products are increasingly prevalent in the pharmaceutical landscape due to their capacity to integrate drug, device, and/or biological products to improve therapeutic outcomes. Navigating the regulatory frameworks surrounding combination products from different authorities, such as the FDA and EMA, can be complex. This article serves as a comprehensive tutorial to elucidate the key steps in the regulatory processes of combination products, with a specific focus on differences between the FDA and EMA standards. This guide will provide regulatory and quality affairs…

FDA OTC Switch Risk Mitigation Strategy for US Sponsors in 2023 – Insight 1 FDA OTC Switch Risk Mitigation Strategy for US Sponsors in 2023 – Insight 1 The transition of pharmaceutical products from prescription (Rx) status to over-the-counter (OTC) availability, known as the Rx to OTC switch, is a strategic move that holds significant implications for market access and patient safety. This article provides a comprehensive step-by-step tutorial on navigating the regulatory landscape, focusing on risk mitigation strategies essential for sponsors in the US. As we delve into each phase, sponsors will gain a clearer understanding of the necessary…

Global Registration Strategy for Prefilled Syringes, Autoinjectors, and Drug-Eluting Devices Global Registration Strategy for Prefilled Syringes, Autoinjectors, and Drug-Eluting Devices The increasing complexity of drug delivery systems has led to the emergence of combination products, including prefilled syringes, autoinjectors, and drug-eluting devices. This tutorial will provide an exhaustive step-by-step guide for regulatory professionals on developing an effective global registration strategy for these products, emphasizing compliance with FDA regulations and the importance of integrating the necessary documentation and processes. Step 1: Understanding Combination Products Combination products, defined as therapeutic and diagnostic products that combine drugs, devices, and/or biological products, are subject…

Case Study: Success and Lessons Learned From Loratadine OTC Switch Case Study: Success and Lessons Learned From Loratadine OTC Switch The transition of a pharmaceutical product from prescription (Rx) status to over-the-counter (OTC) availability is a significant milestone in the regulatory landscape. This comprehensive tutorial provides a step-by-step guide on the Rx to OTC switch, using the case study of Loratadine as a reference point. The following sections outline crucial phases including regulatory pathways, dossier preparation, submission, review, and post-approval commitments, all tailored for professionals in regulatory affairs, market access, and quality assurance. Understanding each of these steps is vital…

How to Prepare a Combination Product Dossier (CTD + Technical File) How to Prepare a Combination Product Dossier (CTD + Technical File) This article provides a comprehensive step-by-step guide for regulatory professionals involved in the preparation of a Combination Product Dossier, focusing on compliant documentation and submission processes. With an emphasis on the FDA’s regulatory framework under 21 CFR Part 4, this guide seeks to facilitate the successful approval of drug-device combinations. Step 1: Understand the Definition and Regulatory Classification of Combination Products Before preparing a combination product dossier, it is crucial to understand what qualifies as a combination product…

Industry Trends: Which Therapeutic Classes Are Likely to Switch Next? Industry Trends: Which Therapeutic Classes Are Likely to Switch Next? The landscape of pharmaceutical regulations continues to evolve, particularly concerning switches from prescription (Rx) to over-the-counter (OTC) classifications. This article outlines the comprehensive steps involved in executing an Rx to OTC switch effectively, focusing on the necessary regulatory frameworks, documentation requirements, and strategic approaches pertinent to the US market. Understanding the implications of such switches is vital for companies engaged in pharma regulatory consulting services, as they navigate these changes and prepare for market access. Step 1: Understanding the Rx…

Primary Mode of Action (PMOA): How It Determines the Lead Regulatory Center Primary Mode of Action (PMOA): How It Determines the Lead Regulatory Center This comprehensive guide outlines the importance of understanding the Primary Mode of Action (PMOA) and its relevance in determining the lead regulatory center for combination products. It provides actionable steps and insights into navigating regulatory pathways effectively. Step 1: Understanding Combination Products and PMOA Combination products, which represent the intersection of drugs, devices, and biological products, are subject to complex regulatory frameworks that ensure their safety and efficacy. According to FDA regulations, the PMOA is a…

EU MDR Classification Rules for Drug-Device Combinations Understanding EU MDR Classification Rules for Drug-Device Combinations Drug-device combinations (combination products) present unique challenges in regulatory classification due to their hybrid nature. For US-based companies looking to navigate the European Union Medical Device Regulation (EU MDR) process, gaining an understanding of these classification rules is essential. This tutorial will provide a step-by-step guide to help regulatory professionals implement the requirements of the EU MDR concerning drug-device combinations. Step 1: Understanding the Definition of Combination Products Before delving into the classification rules applicable to drug-device combinations under EU MDR, it is crucial to…